CClinicalTrials.gg
CompletedNCT01460914Updated Sep 20, 2024

Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment

An observational study in Cutaneous T Cell Lymphoma and Graft Versus Host Disease, sponsored by Dartmouth-Hitchcock Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by Dartmouth-Hitchcock Medical Center · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
34
Ages
18 Years and older
Sex
All
01

Study summary

Extracorporeal Photopheresis (ECP) is a form of apheresis and photodynamic therapy in which the peripheral blood is treated with 8-methoxypsoralen, which is then activated with UV light. ECP is currently a standard therapy for cutaneous T-cell lymphoma (CTCL) and is also effective for graft-versus-host disease (GVHD). The investigators would like to study the outcomes (response rates) of patients receiving ECP treatment and other factors relating to their disease and treatment, as well as procedural events, such as complications.

Read the detailed description

The investigators intend to report outcomes from the inception of this procedure at Dartmouth-Hitchcock Medical Center (DHMC) in May 2008 through 9/30/11. Additionally, the investigators would like to maintain a prospective database of these patients so that new patient data can be collected for updating of outcomes.

02

Conditions studied

  • Cutaneous T Cell Lymphoma
  • Graft Versus Host Disease

Keywords

  • ECP
  • CTCL
  • Extracorporeal photopheresis
  • Cutaneous T Cell Lymphoma
  • GVHD
  • Graft versus host disease
03

In context

Lymphoma

5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.

This study's enrollment of 34 is below the median of 136 across 625 observational studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Dartmouth-Hitchcock Medical Center is the lead sponsor of 472 studies on the registry; 68 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 20 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who receive ECP treatment at DHMC

Inclusion criteria

  • Patients who receive Extracorporeal Photopheresis treatment
  • Treated at Dartmouth-Hitchcock Medical Center
  • Must be 18 years or older

Exclusion criteria

Exclusion Criteria:

  • None specified
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
34 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Response rates

    Response rates to ECP treatment

    Time frame: 1 year

Secondary outcomes

  1. Complications

    Complications to ECP procedures

    Time frame: 1 year

07

Study locations

1 site
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
08

References and documents

Publications

  • Weber LL, Dunbar NM, Meehan KR, Szczepiorkowski ZM, Lansigan F. Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease in a rural hospital. J Clin Apher. 2015 Dec;30(6):359-63. doi: 10.1002/jca.21382. Epub 2015 Feb 17. PubMed 25691106 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01460914
Lead sponsor
Dartmouth-Hitchcock Medical Center
Responsible party
Frederick Lansigan (Assistant Professor of Medicine, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Oct 27, 2011
Start date
Oct 1, 2011
Primary completion
Jan 6, 2015
Completion
Jan 6, 2015
Last update
Sep 20, 2024

Study contacts

Frederick Lansigan, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion